Blockbuster obesity drug Wegovy has been approved in China, opening the door for maker Novo Nordisk to begin selling it in the world’s second-largest economy, where the appetite for similar treatments is surging.
Related Posts
Winemaker Duckhorn Agrees to Be Taken Private in $1.95 Billion Deal
Duckhorn Portfolio has agreed to be taken private by Butterfly Equity in an all-cash deal that values the winemaker at $1.95 billion.
Your Company Is Watching You. And Probably Doing It All Wrong.
Employers often feel like they have to keep an eye on their workers, especially those working remotely. There are bad ways to do it and […]
Decision Time for GM in China: Stay, Scale Back or Go
The country’s sharp shift to EVs and stronger local competition have deflated a key profit engine for the U.S. automaker.